Liverpool Heart and Chest Hospital
Liverpool, Merseyside, L14 3PE, United Kingdom
NCT Number: NCT01942408
Atrial fibrillation (AF) is the commonest condition affecting the rhythm of the heart and causes an irregular and often rapid heartbeat. Developing this condition may cause significant health problems and symptoms that affect normal day-to-day activities. Patients with AF also have a shorter life expectancy on average. Tablets used to try to normalise the heart rhythm rarely work well. As a result, doctors have devised a treatment to try to cure this condition. Special wires (called catheters) are used to deliver heat energy (called ablation) on the inside surface of the heart. This technique has been used more and more in recent years for patients with troublesome symptoms due to AF.
The aim of the treatment is to draw lines of ablation in specific places in the heart. Unfortunately, a lot of patients (almost 50%) get AF again after this treatment and most of these patients have a second treatment performed. It is usually found at this second treatment that gaps have developed in the lines of ablation that were drawn the first time around. The investigators think that electively doing a second treatment to close these gaps a couple of months after the first treatment may mean that fewer of these patients will get AF again in the future. The investigators also want to find out what factors make a line of ablation less likely to develop gaps.
In this study, participants will be assigned to one of two groups:
1. a "standard care" group, who will have a single treatment initially. 2. a "repeat study" group, who will have the initial treatment followed by a second treatment 8-10 weeks later.
For patients in the "repeat study group", investigators will see how many have developed gaps since their first treatment. The investigators will look at where these gaps are and will compare this with information collected during the first treatment to try to work out why the gap has developed. Any gaps found at the second treatment will be closed again.
All participants will then be monitored carefully over 12 months to see how many from each group get AF again. To do this, all participants will be given a handheld heart rhythm monitor to keep until the end of the study. This device is simple to use. Participants will be asked to make a 30 second recording of their heart rhythm each day and also whenever they have symptoms. These recordings will be downloaded at review appointments arranged 6 weeks, 3 months, 6 months and 12 months after the initial ablation procedure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Liverpool, Merseyside, L14 3PE, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
Time frame: 12 months post-initial pulmonary vein isolation (PVI)
The proportion of patients maintaining freedom from AT for 12 months post-initial PVI (after an initial 12 week blanking period)
Time frame: 12 months post-initial PVI
Quality of life 12 months after initial ablation, as quantified by the validated Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire.
Time frame: 12 months post-initial PVI
Time to first AT recurrence after the initial blanking period
Time frame: 4 months post-initial PVI
Comparison of major complication rates (occurring within 30 days after a PVI procedure), to include cardiac tamponade, stroke/transient ischemic attack (TIA), myocardial infarction, pulmonary vein stenosis, phrenic nerve paralysis, oesophageal perforation/atrio-oesophageal fistula, major vascular complications and death
Time frame: 3 months post-initial PVI
Comparison of prevalence, distribution and location of sites of late PV reconnection (8-10 weeks after their initial PVI) between patients with and without early recurrence in the "repeat study" group
Time frame: 4 months post-inital PVI
Correlation between initial Force-Time-Power Integral (as assessed using Visitag™) and a) sites of acute PV reconnection (including those unmasked by adenosine), and b) late PV reconnection (8-10 weeks after their initial PVI)
Liverpool Heart and Chest Hospital NHS Foundation Trust
Other
Pulmonary Vein Re-isolation as a Routine Strategy: a Success Rate Evaluation
Acronym: PRESSURE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsNCT05993897
Arrhythmias, Cardiac, Atrial Fibrillation
Aswān, Aswan Governorate, Egypt
View Trial DetailsNCT05357690
Arrhythmias, Cardiac, Atrial Fibrillation
Rochester, Minnesota, United States
View Trial DetailsNCT05164718
Arrhythmias, Cardiac, Atrial Fibrillation
Drammen, Norway
View Trial Details